ReviewGenes2025
Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.
Review in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparative phylogenetic analysis of breast cancer susceptibility genes reveals evolutionary conservation supporting diagnostic barcode design.Annals of medicine and surgery (2012) · 2026Article
- Real-World Eligibility for Germline Multigene Panel Testing in Breast Cancer: An Evaluation of Current Testing Criteria.Diagnostics (Basel, Switzerland) · 2026Article
- PCSK9 rs562556 variant and survival in BRCA1 mutation carriers and mutation-negative familial breast cancer.NPJ breast cancer · 2026Article
- Article
- Perception of Family Genetic Testing for Hereditary Breast and Ovarian Cancer: A Survey of Patients and General Public.Journal of Korean medical science · 2026Article
- Association of genetic variation in TLR4 and TLR9 genes with susceptibility to invasive ductal breast carcinoma.Molecular biology reports · 2026Article
- Review
- Advancing Germline Genetic Testing for Breast Cancer in Resource-Restricted Settings: Evidence, Barriers, and a Practical Roadmap for Implementation.Breast cancer (Dove Medical Press) · 2026Review
- Cost-effectiveness and budget impact of breast cancer genetic profiling in Egypt.Ecancermedicalscience · 2026Review
- Cosmetic Habits Associated With Breast Cancer in Benin: A Multicenter Case-Control Study.Journal of cosmetic dermatology · 2026Article
- Night shift work and breast cancer: from etiopathology to precision risk analysis.NPJ breast cancer · 2025Review
- The relationship of ST6GAL1 with clinicopathological and prognostic factors in breast carcinomas.Saudi medical journal · 2025Article
- Generating a database by calculating the pathogenic variants and allele frequencies detected in hereditary cancers using genomic data: A nation study.Global medical genetics · 2025Article
- Emotional distress and quality of life in high and moderate penetrance germline mutations carriers diagnosed with breast cancer: a preliminary study.Medicine and pharmacy reports · 2025Article
- Targeting Molecular Pathways in Breast Cancer Using Plant-Derived Bioactive Compounds: A Comprehensive Review.Journal of experimental pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women carrying pathogenic/likely pathogenic (P/LP) variants in moderate- or high-penetrance genes have an increased risk of developing breast cancer. However, most P/LP variants associated with breast cancer risk show incomplete penetrance. Age, gender, family history, polygenic risk, lifestyle, reproductive, hormonal, and environmental factors can affect the expressivity and penetrance of the disease. However, there are gaps in translating how individual genomic variation affects phenotypic presentation. The expansion of criteria for genetic testing and the increasing utilization of comprehensive genetic panels may enhance the identification of individuals carrying P/LP variants linked to hereditary breast cancer. Individualized risk assessment could facilitate the implementation of personalized risk-reduction strategies for these individuals. Preventive interventions encompass lifestyle modifications, chemoprevention, enhanced surveillance through breast imaging, and risk-reducing surgeries. This review addresses the current literature's inconsistencies and limitations, particularly regarding risk factors and the intensity of preventive strategies for women with P/LP variants in moderate- and high-penetrance genes. In addition, it synthesizes the latest evidence on risk assessment and primary and secondary prevention in women at high risk of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.